Form 4: GoodRx Director Trevor Bezdek Receives RSU Grant

Director Trevor Bezdek was granted 110,294 restricted stock units as part of his compensation package with GoodRx Holdings, Inc.

Summary

• Director Trevor Bezdek acquired 110,294 restricted stock units (RSUs) on June 8, 2026.
• Each RSU represents a contingent right to receive one share of Class A common stock.
• The grant is subject to a 100% vesting schedule on December 31, 2027, contingent upon continued service.
• The transaction was granted at a price of $0 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding director compensation, which is a routine corporate governance event.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership through a multi-year vesting schedule ending in late 2027.

Negatives

• Potential for future shareholder dilution upon the eventual vesting and issuance of the underlying Class A common stock.

Risks

• Vesting is contingent upon continued service, creating a dependency on the director's ongoing tenure.
• Market volatility could impact the future value of the equity granted.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term performance and retention in the competitive digital health and pharmacy technology sectors.

Comparison to Industry Standards

• The use of RSUs as a primary vehicle for director compensation is consistent with standard practices among mid-cap technology and healthcare companies.
• The vesting period of approximately 1.5 years is standard for director equity retention programs.

Related Party Transactions

• The filing discloses holdings by various Grantor Retained Annuity Trusts (GRATs) associated with the reporting person and his spouse.

Stakeholder Impact

• Shareholders may experience minor dilution upon the vesting of these units in 2027.

Next Steps

• Vesting of the 110,294 RSUs on December 31, 2027.

Key Dates

Keywords

GoodRx, GDRX, Form 4, Insider Trading, Equity Compensation, Trevor Bezdek